Systemic Thyroid Hormone Status during Levothyroxine Therapy in Hypothyroidism: A Systematic Review and Meta-Analysis

Elizabeth A. McAninch, Kumar B. Rajan, Corinne H. Miller, Antonio C. Bianco

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Context: The standard of care for overt hypothyroidism is levothyroxine (LT4) at doses that normalize serum TSH levels. Whether this approach universally restores thyroid hormone signaling is unknown. Objective: To review studies of overt hypothyroidism in which participants received LT4 to normalize serum TSH levels and measure other objective markers of thyroid hormone signaling. Design: Databases were searched for studies that reported objective markers of thyroid hormone signaling [serum low-density lipoprotein (LDL), total cholesterol (TC), SHBG, creatine kinase and/or ferritin levels; cognition, energy expenditure, and/or renal function] during LT4 monotherapy for overt, primary hypothyroidism among nonpregnant adults with normal serum TSH levels. For studies with LDL, TC, and SHBG outcomes, the data were pooled using random effects meta-analysis. Results: A total of 99 studies met the inclusion criteria, including 65 reporting serum cholesterol data. The meta-analysis showed that LT4-treated participants with hypothyroidism but normal serum TSH levels had 3.31 ± 1.64 mg/dL greater serum LDL (P = 0.044) and 9.60 ± 3.55 mg/dL greater serum TC (P = 0.007) compared with controls. In studies that had not concomitantly assessed healthy controls, serum LDL was 138.3 ± 4.6 mg/dL (P < 0.001) and serum TC was 209.6 ± 3.4 mg/dL (P < 0.001). A meta-analysis of two studies showed no important differences between the SHBG levels of LT4-treated participants and controls. Conclusions: In studies of LT4 monotherapy at doses that normalized serum TSH for overt, primary hypothyroidism, not all systemic biological markers of thyroid hormone signaling were normalized, including the serum LDL and TC levels.

Original languageEnglish (US)
Pages (from-to)4533-4542
Number of pages10
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number12
DOIs
StatePublished - Jan 1 2018

Fingerprint

Hypothyroidism
Thyroxine
Thyroid Hormones
Meta-Analysis
LDL Lipoproteins
Cholesterol
Serum
Therapeutics
LDL Cholesterol
Ferritins
Creatine Kinase
Standard of Care
Cognition
Energy Metabolism
Biomarkers
Databases
Kidney

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Systemic Thyroid Hormone Status during Levothyroxine Therapy in Hypothyroidism : A Systematic Review and Meta-Analysis. / McAninch, Elizabeth A.; Rajan, Kumar B.; Miller, Corinne H.; Bianco, Antonio C.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 12, 01.01.2018, p. 4533-4542.

Research output: Contribution to journalArticle

@article{a7364294c1e54e02aa624d144d0543a1,
title = "Systemic Thyroid Hormone Status during Levothyroxine Therapy in Hypothyroidism: A Systematic Review and Meta-Analysis",
abstract = "Context: The standard of care for overt hypothyroidism is levothyroxine (LT4) at doses that normalize serum TSH levels. Whether this approach universally restores thyroid hormone signaling is unknown. Objective: To review studies of overt hypothyroidism in which participants received LT4 to normalize serum TSH levels and measure other objective markers of thyroid hormone signaling. Design: Databases were searched for studies that reported objective markers of thyroid hormone signaling [serum low-density lipoprotein (LDL), total cholesterol (TC), SHBG, creatine kinase and/or ferritin levels; cognition, energy expenditure, and/or renal function] during LT4 monotherapy for overt, primary hypothyroidism among nonpregnant adults with normal serum TSH levels. For studies with LDL, TC, and SHBG outcomes, the data were pooled using random effects meta-analysis. Results: A total of 99 studies met the inclusion criteria, including 65 reporting serum cholesterol data. The meta-analysis showed that LT4-treated participants with hypothyroidism but normal serum TSH levels had 3.31 ± 1.64 mg/dL greater serum LDL (P = 0.044) and 9.60 ± 3.55 mg/dL greater serum TC (P = 0.007) compared with controls. In studies that had not concomitantly assessed healthy controls, serum LDL was 138.3 ± 4.6 mg/dL (P < 0.001) and serum TC was 209.6 ± 3.4 mg/dL (P < 0.001). A meta-analysis of two studies showed no important differences between the SHBG levels of LT4-treated participants and controls. Conclusions: In studies of LT4 monotherapy at doses that normalized serum TSH for overt, primary hypothyroidism, not all systemic biological markers of thyroid hormone signaling were normalized, including the serum LDL and TC levels.",
author = "McAninch, {Elizabeth A.} and Rajan, {Kumar B.} and Miller, {Corinne H.} and Bianco, {Antonio C.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1210/jc.2018-01361",
language = "English (US)",
volume = "103",
pages = "4533--4542",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "12",

}

TY - JOUR

T1 - Systemic Thyroid Hormone Status during Levothyroxine Therapy in Hypothyroidism

T2 - A Systematic Review and Meta-Analysis

AU - McAninch, Elizabeth A.

AU - Rajan, Kumar B.

AU - Miller, Corinne H.

AU - Bianco, Antonio C.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Context: The standard of care for overt hypothyroidism is levothyroxine (LT4) at doses that normalize serum TSH levels. Whether this approach universally restores thyroid hormone signaling is unknown. Objective: To review studies of overt hypothyroidism in which participants received LT4 to normalize serum TSH levels and measure other objective markers of thyroid hormone signaling. Design: Databases were searched for studies that reported objective markers of thyroid hormone signaling [serum low-density lipoprotein (LDL), total cholesterol (TC), SHBG, creatine kinase and/or ferritin levels; cognition, energy expenditure, and/or renal function] during LT4 monotherapy for overt, primary hypothyroidism among nonpregnant adults with normal serum TSH levels. For studies with LDL, TC, and SHBG outcomes, the data were pooled using random effects meta-analysis. Results: A total of 99 studies met the inclusion criteria, including 65 reporting serum cholesterol data. The meta-analysis showed that LT4-treated participants with hypothyroidism but normal serum TSH levels had 3.31 ± 1.64 mg/dL greater serum LDL (P = 0.044) and 9.60 ± 3.55 mg/dL greater serum TC (P = 0.007) compared with controls. In studies that had not concomitantly assessed healthy controls, serum LDL was 138.3 ± 4.6 mg/dL (P < 0.001) and serum TC was 209.6 ± 3.4 mg/dL (P < 0.001). A meta-analysis of two studies showed no important differences between the SHBG levels of LT4-treated participants and controls. Conclusions: In studies of LT4 monotherapy at doses that normalized serum TSH for overt, primary hypothyroidism, not all systemic biological markers of thyroid hormone signaling were normalized, including the serum LDL and TC levels.

AB - Context: The standard of care for overt hypothyroidism is levothyroxine (LT4) at doses that normalize serum TSH levels. Whether this approach universally restores thyroid hormone signaling is unknown. Objective: To review studies of overt hypothyroidism in which participants received LT4 to normalize serum TSH levels and measure other objective markers of thyroid hormone signaling. Design: Databases were searched for studies that reported objective markers of thyroid hormone signaling [serum low-density lipoprotein (LDL), total cholesterol (TC), SHBG, creatine kinase and/or ferritin levels; cognition, energy expenditure, and/or renal function] during LT4 monotherapy for overt, primary hypothyroidism among nonpregnant adults with normal serum TSH levels. For studies with LDL, TC, and SHBG outcomes, the data were pooled using random effects meta-analysis. Results: A total of 99 studies met the inclusion criteria, including 65 reporting serum cholesterol data. The meta-analysis showed that LT4-treated participants with hypothyroidism but normal serum TSH levels had 3.31 ± 1.64 mg/dL greater serum LDL (P = 0.044) and 9.60 ± 3.55 mg/dL greater serum TC (P = 0.007) compared with controls. In studies that had not concomitantly assessed healthy controls, serum LDL was 138.3 ± 4.6 mg/dL (P < 0.001) and serum TC was 209.6 ± 3.4 mg/dL (P < 0.001). A meta-analysis of two studies showed no important differences between the SHBG levels of LT4-treated participants and controls. Conclusions: In studies of LT4 monotherapy at doses that normalized serum TSH for overt, primary hypothyroidism, not all systemic biological markers of thyroid hormone signaling were normalized, including the serum LDL and TC levels.

UR - http://www.scopus.com/inward/record.url?scp=85062469595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062469595&partnerID=8YFLogxK

U2 - 10.1210/jc.2018-01361

DO - 10.1210/jc.2018-01361

M3 - Article

C2 - 30124904

AN - SCOPUS:85062469595

VL - 103

SP - 4533

EP - 4542

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 12

ER -